Calcemic activity of 19-Nor-1,25(OH)2D2 decreases with duration of treatment

Journal of the American Society of Nephrology

Volumn 11, Issue 11, 2000, Pages 2088-2094

  Brown, A J ^a   Finch, J ^a   Takahashi, F ^a   Slatopolsky, E ^a  

^a Department of Internal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

19 NOR 1,25 DIHYDROXYERGOCALCIFEROL; PARATHYROID HORMONE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE TARGETING; HORMONAL REGULATION; INTESTINE ABSORPTION; NONHUMAN; PRIORITY JOURNAL; RAT; SECONDARY HYPERPARATHYROIDISM; SUBSTITUTION THERAPY;

EID: 0033755011     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Pathogenesis of secondary hyperparathyroidism
2. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat
3. Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene
4. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia
5. 2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats
6. 2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis
7. 2
8. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion
9. Effects of calcitriol, 22-oxacalcitriol, and calcipotriol on serum calcium and parathyroid hormone gene expression
10. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study
11. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism
12. 1 Alpha-hydroxy-vitamin D2: A new look at an 'old' compound
13. Protein-binding properties of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a synthetic analogue of 1 alpha,25-dihydroxyvitamin D3
14. Metabolism and transporting system of 22-oxacalcitriol
15. On the mechanisms for the selective action of vitamin D analogs
16. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine
17. 2 on calcium and phosphorus resorption in bone
18. Vitamin D analogues
19. New active analogues of vitamin D with low calcemic activity
20. Origin of the use of calcipotriol in psoriasis treatment
21. Comparison of calcipotriol with selected metabolites and analogues of vitamin D3: Effects on cell growth regulation in vitro and calcium metabolism in vivo
22. 2, a vitamin D analog with reduced bone resorbing activity in vitro
23. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content
24. The nuclear vitamin D receptor: Biological and molecular regulatory properties
25. Distinct conformational changes induced by 20-epi analogues of 1 alpha,25-dihydroxyvitamin D3 are associated with enhanced activation of the vitamin D receptor
26. Selective interaction of vitamin D receptor with transcriptional co-activators by a vitamin D analog
27. 20-epi Analogues of 1,25-dihydroxyvitamin D3 are highly potent inducers of DRIP co-activator complex binding to the vitamin D3 receptor
28. Selective recognition of vitamin D receptor conformations mediates promoter selectivity of vitamin D analogs
29. The effect of 22-oxacalcitriol on serum calcitriol
30. Membrane receptors for steroid hormones: A case for specific cell surface binding sites for Vitamin D metabolites and estrogens
31. 3: Past, present, and future
32. 3 and is involved in the rapid actions of the hormone